Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2007 Sep 2:361–389. doi: 10.1016/B978-012498340-3/50026-9

Interferons Alpha, Beta, and Omega

Anthony Meager 1
Editors: Anthony R Mire-Sluis1, Robin Thorpe1
PMCID: PMC7155463

Publisher Summary

Interferon alpha (IFN-α) is a mixture of closely related proteins, termed “subtypes,” expressed from distinct chromosomal genes. Interferon β (IFN-β) is a single protein species and is molecularly related to IFN-α subtypes, although it is antigenically distinct from them. IFN omega (IFN-ω) is antigenically distinct from IFN-α and IFN-β but is molecularly related to both. The genes of three IFN subtypes are tandemly arranged on the short arm of chromosome 9. They are transiently expressed following induction by various exogenous stimuli, including viruses. They are synthesized from their respective mRNAs for relatively short periods following gene activation and are secreted to act, via specific cell surface receptors, on other cells. IFN-α subtypes are secreted proteins and as such are transcribed from mRNAs as precursor proteins, pre-IFN-α, containing N-terminal signal polypeptides of 23 hydrophobic amino acids (aa) mainly. Pre-IFN-β contains 187 aa, of which 21 comprise the N-terminal signal polypeptide and 166 comprise the mature IFN-β protein. IFN-ω contains 195 aa—the N-terminal 23 comprising the signal sequence and the remaining 172, the mature IFN-ω protein. At the C-terminus, the aa sequence of IFN-ω is six residues longer than that of IFN-α or IFN-β proteins. IFN-α, as a mixture of subtypes, and IFN-ω may be produced together following viral infection of null lymphocytes or monocytes/macrophages. The biological activities of IFNs are mostly dependent upon protein synthesis with selective subsets of proteins mediating individual activities. IFNs can also stimulate indirect antiviral and antitumor mechanisms, depending upon cellular differentiation and the induction of cytotoxic activity.

References

  1. Aboud M., Hassan Y. Accumulation and breakdown of RNA-deficient intracellular virus particles in interferon-treated NIH 3T3 cells chronically producing Moloney murine leukaemia v. J. Virol. 1983;45:489–495. doi: 10.1128/jvi.45.2.489-495.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ackrill A.M., Foster G.R., Laxton C.D., Flavell D.M., Stark G.R., Kerr I.M. Inhibition of the cellular response to interferons by products of the adenovirus type 5 E1A oncogene. Nucleic Acids Res. 1991;19:4387–4393. doi: 10.1093/nar/19.16.4387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Adolf G.R. Antigenic structure of human interferon col (interferon alpha II): comparison with other human interferons. J. Gen. Virol. 1987;68:1669–1676. doi: 10.1099/0022-1317-68-6-1669. [DOI] [PubMed] [Google Scholar]
  4. Adolf G.R. Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ωl: evidence that IFN-ωl is a component of human leukocyte IFN. Virology. 1990;175:410–417. doi: 10.1016/0042-6822(90)90425-q. [DOI] [PubMed] [Google Scholar]
  5. Adolf G.R., Maurer-Fogy I., Kalsner I., Cantell K. Purification and characterisation of natural interferon ωl: two alternative cleavage sites for the signal peptidase. J. Biol. Chem. 1990;265:9290–9295. [PubMed] [Google Scholar]
  6. Adolf G.R., Kalsner I., Ahorn H., Maurer-Fogy I., Cantell K. Natural human interferon-α2 is O-glycosylated. Biochem. J. 1991;276:511–518. doi: 10.1042/bj2760511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Adolf G.R., Frühbeis B., Hauptmann R. Human interferon ωl: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein. Biochim. Biophys. Acta. 1991;1089:167–1740. doi: 10.1016/0167-4781(91)90004-6. [DOI] [PubMed] [Google Scholar]
  8. Aguet M. High affinity binding of 125I-labelled mouse interferon to a specific cell surface receptor. Nature. 1980;284:459–461. doi: 10.1038/284459a0. [DOI] [PubMed] [Google Scholar]
  9. Aguet M., Grobke M., Dreiding P. Various human interferon a subclasses cross-react with common receptors: their binding activities correlate with their specific biological activities. Virology. 1984;132:211–216. doi: 10.1016/0042-6822(84)90105-3. [DOI] [PubMed] [Google Scholar]
  10. Aguet M., Dembic Z., Merlin G. Molecular cloning and expression of the human interferon-γ receptor. Cell. 1988;55:273–280. doi: 10.1016/0092-8674(88)90050-5. [DOI] [PubMed] [Google Scholar]
  11. Alldridge L.C., O'Farrell M.K., Dealtry G.B. Interferon β increases expression of vimentin at the mRNA and protein levels in differentiated embryonal carcinoma (PSMB) cells. Exp. Cell Res. 1989;185:387–393. doi: 10.1016/0014-4827(89)90308-x. [DOI] [PubMed] [Google Scholar]
  12. Allen G., Diaz M.O. Nomenclature of the human interferon proteins. J. Interferon and Cytokine Res. 1996;16:181–184. doi: 10.1089/jir.1996.16.181. [DOI] [PubMed] [Google Scholar]
  13. Allen G., Fantes K.H. A family of structural genes for human lymphoblastoid (leukocyte-type) interferon. Nature. 1980;287:408–411. doi: 10.1038/287408a0. [DOI] [PubMed] [Google Scholar]
  14. Antonelli G., Currenti M., Turriziani O., Dianzani F. Neutralizing antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. J. Infect. Dis. 1991;163:882–885. doi: 10.1093/infdis/163.4.882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Au W.-C., Raj N.K.B., Pine R., Pitha P.M. Distinct activation of murine interferon-a promoter region by IRF-l/ISGF-2 and virus infection. Nucleic Acids Res. 1992;20:2877–2884. doi: 10.1093/nar/20.11.2877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Baldini L., Cortelezzi A., Polli N. Human recombinant interferon α-2C enhances the expression of class II HLA antigens on hairy cells. Blood. 1986;67:458–464. [PubMed] [Google Scholar]
  17. Balkwill F.R. Cytokines in Cancer Therapy. Oxford University Press; New York: 1989. pp. 8–53. [Google Scholar]
  18. Bange F.-C., Vogel U., Flohr T., Kiekenbeck M., Denecke B., Bottger E.C. IFP35 is an interferon-induced leucine zipper protein that undergoes interferon-regulated cellular redistribution. J. Biol. Chem. 1994;269:1091–1098. [PubMed] [Google Scholar]
  19. Baron S., Tyring S.K., Fleischmann W.R.J. The interferons: mechanisms of action and clinical applications. J. Am. Med. Assoc. 1991;266:1375–1383. doi: 10.1001/jama.266.10.1375. [DOI] [PubMed] [Google Scholar]
  20. Bazan J.F. Shared architecture of the hormone binding domains in type I and II interferon receptors. Cell. 1990;61:753–754. doi: 10.1016/0092-8674(90)90182-e. [DOI] [PubMed] [Google Scholar]
  21. Bazan J.F. Haemopoietic receptors and helical cytokines. Immunol. Today. 1990;11:350–354. doi: 10.1016/0167-5699(90)90139-z. [DOI] [PubMed] [Google Scholar]
  22. Beattie E., Tartaglia J., Paoletti E. Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology. 1991;183:419–422. doi: 10.1016/0042-6822(91)90158-8. [DOI] [PubMed] [Google Scholar]
  23. Benoit P., Maguire D., Plavec I., Kocher H., Tovey M., Meyer F. A monoclonal antibody to recombinant human IFN-α receptor inhibits biologic activity of several species of human IFN-α, IFN-β and IFN-μ. J. Immunol. 1993;150:707–716. [PubMed] [Google Scholar]
  24. Berglund O., Engman K., Ehrnst A. Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon a and zidovudine. J. Infect. Dis. 1991;163:710–715. doi: 10.1093/infdis/163.4.710. [DOI] [PubMed] [Google Scholar]
  25. Bottomly J.M., Toy J.L. Clinical side effects and toxicities of interferon. In: Finter N.B., Oldham R.K., editors. Interferon, vol. 4. In vivo and Clinical Studies. Elsevier; Oxford: 1985. pp. 155–180. [Google Scholar]
  26. Bovolenta C., Driggers P.H., Marks M.S. Vol. 91. 1994. Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family; pp. 5046–5050. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Brack C., Nagata S., Mantei N., Weissmann C. Molecular analysis of the human interferon-α gene family. Gene. 1981;15:379–394. doi: 10.1016/0378-1119(81)90181-5. [DOI] [PubMed] [Google Scholar]
  28. Branca A.A. The interferon receptors. In Vitro Cell Dev. Biol. 1988;24:155–165. doi: 10.1007/BF02623541. [DOI] [PubMed] [Google Scholar]
  29. Branca A.A., Baglioni C. Evidence that types I and II interferons have different receptors. Nature. 1981;294:768–770. doi: 10.1038/294768a0. [DOI] [PubMed] [Google Scholar]
  30. Brand C.M., Leadbeater L., Lechner K., Gisslinger H. Successful retreatment of an anti-interferon resistant polycythaemic vera patient with lymphoblastoid inter feron-αNl and in vitro studies on the specif. Br. J. Haematol. 1993;86:216–218. doi: 10.1111/j.1365-2141.1994.tb03283.x. [DOI] [PubMed] [Google Scholar]
  31. Cantell K., Hirvonen S. Preparation of human leukocyte interferon for clinical use. Tex. Rep. Biol. Med. 1977;35:138–144. [PubMed] [Google Scholar]
  32. Capon D.J., Shepard H.M., Goeddel D.V. Two distinct families of human and bovine interferon-α genes are coordinately expressed and encode functional polypeptides. Mol. Cell. Biol. 1985;5:768–779. doi: 10.1128/mcb.5.4.768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Caput D., Beutler B., Hartog K., Thayer R., Brown-Shimer S., Cerami A. Vol. 83. 1986. Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators; pp. 1670–1674. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Cayley P.J., Davies J.A., McCullagh K.G., Kerr I.M. Activation of the ppp(A2'p)nA system in interferon-treated, herpes simplex virus-infected cells and evidence for novel inhibitors of the ppp(A2'p)nA-dependent. Eur. J. Biochem. 1984;143:165–174. doi: 10.1111/j.1432-1033.1984.tb08355.x. [DOI] [PubMed] [Google Scholar]
  35. Chebath J., Merlin G., Metz R., Benech P., Revel M. Interferon-induced 56,000 Mr protein and its mRNA in human cells: molecular cloning and partial sequence of the cDNA. Nucleic Acids Res. 1983;11:1213–1226. doi: 10.1093/nar/11.5.1213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Chebath J., Benech P., Revel M., Vigneron M. Constitutive expression of (2'-5') oligo A synthetase confers resistance to picornavirus infection. Nature. 1987;330:587–588. doi: 10.1038/330587a0. [DOI] [PubMed] [Google Scholar]
  37. Cheng S., Lutfalla G., Uzé G., Chumakov I., Gardiner K. GART, SON, IFNAR, and CRF-24 genes cluster on human chromosome 21 and mouse chromosome 16. Mammal Genome. 1993;3:338–342. doi: 10.1007/BF00357094. [DOI] [PubMed] [Google Scholar]
  38. Choubey D., Lengyel P. Interferon action: nucleolar and nucleoplasmic localization of the interferon-inducible 72-kD protein that is encoded by the If: 204 gene from the gene 200 cl. J. Cell Biol. 1992;116:1333–1341. doi: 10.1083/jcb.116.6.1333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Clark L., Hay R.T. Sequence requirement for specific interaction of an enhancer binding protein (EBP1) with DNA. Nucleic Acids Res. 1989;17:499–516. doi: 10.1093/nar/17.2.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Clarke P.A., Schwemmle M., Schickinger J., Hilse K., Clemens M. Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI. Nucleic Acids Res. 1991;19:243–248. doi: 10.1093/nar/19.2.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Cleary C.M., Donnelly R.J., Soh J., Mariano T.M., Pestka S. Knockout and reconstitution of a functional human type I interferon receptor complex. J. Biol. Chem. 1994;269:18747–18749. [PubMed] [Google Scholar]
  42. Colamonici O.R., D'Allesandro F., Diaz M.O., Gregory L., Neckers M., Nordan R. Vol. 87. 1990. Characterization of three monoclonal antibodies that recognize the IFNα2 receptor; pp. 7230–7234. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Colamonici O.R., Pfeffer L.M., D'Alessandro F. Multichain structure of the IFN-α receptor on hematopoietic cells. J. Immunol. 1992;148:2126–2132. [PubMed] [Google Scholar]
  44. Colamonici O., Domanski P., Sweitzer S., Larner A., Buller R. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon α transmembrane signaling. J. Biol. Chem. 1995;270:15974–15978. doi: 10.1074/jbc.270.27.15974. [DOI] [PubMed] [Google Scholar]
  45. Constantinescu S.N., Croze E., Wang C. Vol. 91. 1994. Role of interferon α/β receptor chain 1 in the structure and transmembrane signalling of the interferon α/β receptor complex; pp. 9602–9606. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Constantoulakis P., Campbell M., Felber B.K., Nasioulas G., Afonina E., Parlakis G.N. Inhibition of Rev-mediated HIV-1 expression by an RNA binding protein encoded by the interferon-inducible 9-27 gene. Science. 1993;259:1314–1316. doi: 10.1126/science.7680491. [DOI] [PubMed] [Google Scholar]
  47. Contente S., Kenyon K., Rimoldi D., Friedman R.M. Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science. 1990;249:796–798. doi: 10.1126/science.1697103. [DOI] [PubMed] [Google Scholar]
  48. Dandoy F., Kelley K., De Maeyer-Guignard J., De Maeyer E., Pitha P. Linkage analysis of the murine interferon-α locus on chromosome 4. J. Exp. Med. 1984;160:294–302. doi: 10.1084/jem.160.1.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Dandoy F., De Maeyer E., Bonhomme F., Guenet J., De Maeyer-Guignard J. Segregation of restriction fragment length polymorphism in an interspecies cross of laboratory and wild mice indicates tight linkage of the murine IFN-β gen. J. Virol. 1985;56:216–220. doi: 10.1128/jvi.56.1.216-220.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Degrave W., Derynck R., Tavernier J., Haegeman G., Fiers W. Nucleotide sequence of the chromosomal gene for human fibroblast (β1) interferon and of the flanking regions. Gene. 1981;14:137–143. doi: 10.1016/0378-1119(81)90109-8. [DOI] [PubMed] [Google Scholar]
  51. Delcayre A.X., Salas F., Mathur S., Kovats K., Lotz M., Lernhardt W. Epstein Barr virus/complement C3d receptor is an interferon a receptor. EMBO J. 1991;10:919–926. doi: 10.1002/j.1460-2075.1991.tb08025.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. De Maeyer E., De Maeyer-Guignard J. Wiley Interscience; Amsterdam: 1988. Interferons and Other Regulatory Cytokines. [Google Scholar]
  53. Derynck R., Content J., De Clercq E. Isolation and structure of a human fibroblast interferon gene. Nature. 1980;285:542–547. doi: 10.1038/285542a0. [DOI] [PubMed] [Google Scholar]
  54. Derynck R., Devos R., Remant E. Isolation and characterisation of a human fibroblast interferon gene and its expression in Escherichia coli. Rev. Infect. Dis. 1981;3:1186–1195. doi: 10.1093/clinids/3.6.1186. [DOI] [PubMed] [Google Scholar]
  55. De Wit R., Schattenkerk J.K., Boucher C.A., Bakker P.J., Veenhof K.H., Danner S.A. Clinical and virological effects of high-dose recombinant interferon alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet. 1988;ii:1214–1217. doi: 10.1016/s0140-6736(88)90810-0. [DOI] [PubMed] [Google Scholar]
  56. Diaz M.O., Allen G. Nomenclature of the human interferon genes. J. Interferon Res. 1993;13:443–444. doi: 10.1089/jir.1993.13.443. [DOI] [PubMed] [Google Scholar]
  57. Dinter H., Hauser H. Cooperative interaction of multiple DNA elements in the interferon-β promoter. Eur. J. Biochem. 1987;166:103–109. doi: 10.1111/j.1432-1033.1987.tb13488.x. [DOI] [PubMed] [Google Scholar]
  58. Domanski P., Witte M., Kellum M. Cloning and expression of a long form of the β subunit of the interferon αβ receptor that is required for signalling. J. Biol. Chem. 1995;270:21606–21611. doi: 10.1074/jbc.270.37.21606. [DOI] [PubMed] [Google Scholar]
  59. Douglas J.M., Eron L.J., Judson F.N. A randomized trial of combination therapy with intralesional interferon alpha 2b and podophyllin versus podophyllin alone for the therapy of anogenital warts. J. Infect. Dis. 1990;162:52–59. doi: 10.1093/infdis/162.1.52. [DOI] [PubMed] [Google Scholar]
  60. Douglas R.M., Moore B.W., Miles H.B. Prophylactic efficacy of intranasal alpha-2 interferon against rhinovirus infections in the family setting. N. Engl. J. Med. 1986;314:65–70. doi: 10.1056/NEJM198601093140201. [DOI] [PubMed] [Google Scholar]
  61. Du W., Maniatis T. Vol. 89. 1992. An ATF/CREB binding site protein is required for virus induction of the human interferon β gene; pp. 2150–2154. (Proc. Nad Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Durbin J., Hackenmiller R., Simon M., Levy D. Targeted disruption of the mouse Stat 1 gene results in compromised innate immunity to viral disease. Cell. 1996;84:443–450. doi: 10.1016/s0092-8674(00)81289-1. [DOI] [PubMed] [Google Scholar]
  63. Dworkin-Rasd E., Dworkin M.B., Swetiy P. Molecular cloning of human alpha and beta genes from Namalwa cells. J. Interferon Res. 1982;2:575–585. doi: 10.1089/jir.1982.2.575. [DOI] [PubMed] [Google Scholar]
  64. Ebers G.C. Treatment of multiple sclerosis. Lancet. 1994;343:275–278. doi: 10.1016/s0140-6736(94)91119-3. [DOI] [PubMed] [Google Scholar]
  65. Eid R., Mogensen K.E. Isolated interferon alpha-receptor complexes stabilised in vitro. FEBS Lett. 1983;156:157–160. doi: 10.1016/0014-5793(83)80268-3. [DOI] [PubMed] [Google Scholar]
  66. Emanuel S.L., Pestka S. Human interferon-αA, -α2 and -α2 (Arg) genes in genomic DNA. J. Biol. Chem. 1993;268:12565–12569. [PubMed] [Google Scholar]
  67. Epstein C.J., McManus N.H., Epstein L.B., Branca A.A., D'Alessandro S.B., Baglioni C. Direct evidence that the gene product of the human chromosome 21 locus, IFRC, is the interferon-α receptor. Biochem. Biophys. Res. Commun. 1982;107:1060–1066. doi: 10.1016/0006-291x(82)90629-5. [DOI] [PubMed] [Google Scholar]
  68. Evinger M., Maeda S., Pestka S. Recombinant human leukocyte interferon produced in bacteria has antiproliferative activity. J. Biol. Chem. 1981;256:2113–2114. [PubMed] [Google Scholar]
  69. Faltynek C.R., Branca A.A., McCandless S., Baglioni C. Vol. 80. 1983. Characterization of an interferon receptor on human lymphoblastoid cells; pp. 3269–3273. (Proc. Nad Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Fan C.-M., Maniatis T. Two different virus-inducible elements are required for human β-interferon gene regulation. EMBO J. 1989;8:101–110. doi: 10.1002/j.1460-2075.1989.tb03353.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Fantes K.H. Purification, concentration and physico-chemical properties of interferons. In: Finter N.B., editor. Interferons. North-Holland; New York: 1966. pp. 118–180. [Google Scholar]
  72. Feldmann M., Londei M., Buchan G. Interferons and autoimmunity. In: Gresser I., editor. Interferon 9. Academic Press; Amsterdam: 1989. pp. 73–90. [Google Scholar]
  73. Fellous M., Kamoun M., Gresser I., Bono R. Enhanced expression of HLA antigens and α2-microglobulin on interferon-treated human lymphoid cells. Eur. J. Immunol. 1979;9:446–449. doi: 10.1002/eji.1830090606. [DOI] [PubMed] [Google Scholar]
  74. Fellous A., Ginzburg I., Littauer U.Z. Modulation of tubulin mRNA levels by interferon in human lymphoblastoid cells. EMBO J. 1982;1:835–839. doi: 10.1002/j.1460-2075.1982.tb01256.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Finter N.B. Why are there so many subtypes of alpha-interferons. J. Interferon Res. 1991:185–194. Special Issue, Jan. 1991, [Google Scholar]
  76. Flores I., Mirano M., Pestka S. Human interferon omega (ω) binds to the α/β receptor. J. Biol. Chem. 1991;266:19875–19877. [PubMed] [Google Scholar]
  77. Fossa S.D., Lehne G., Gunderson R., Hjelmaas U., Holdener E.E. Recombinant interferon a-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of ant. Int. J. Cancer. 1992;50:868–870. doi: 10.1002/ijc.2910500606. [DOI] [PubMed] [Google Scholar]
  78. Foster G.M., Ackrill A.M., Goldin R.D., Kerr I.M., Thomas H.C., Stark G.R. Vol. 88. 1991. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons α and γ and double-stranded RNA; pp. 2888–2892. (Proc. Nad Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Freund M., von Wussow P., Diedrich H. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibo. Br. J. Haematol. 1989;72:350–356. doi: 10.1111/j.1365-2141.1989.tb07715.x. [DOI] [PubMed] [Google Scholar]
  80. Friedland G.H., Klein R.S., Saltzman B.R., The Interferon Alpha Study Group A randomized placebo-controlled trial of recombinant human interferon alpha 2a in patients with AIDS. J. Acquir. Immune Defic. Syndr. 1988;1:111–118. [PubMed] [Google Scholar]
  81. Fujita T., Ohno S., Yasumitsu H., Taniguchi T. Delimitation and properties of DNA sequences required for the regulated expression of human interferon-β gene. Cell. 1985;41:489–496. doi: 10.1016/s0092-8674(85)80022-2. [DOI] [PubMed] [Google Scholar]
  82. Fujita T., Sakakibara J., Sudo Y., Miyamoto M., Kimura Y., Taniguchi T. Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN-β gene regulatory elements. EMBO J. 1988;7:3397–3405. doi: 10.1002/j.1460-2075.1988.tb03213.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Fujita T., Miyamoto M., Kimura Y., Hammer J., Taniguchi T. Involvement of a cis-element that binds an H2TF-1/NF-ϰB like factor(s) in virus-induced interferon-β expression. Nucleic Acids Res. 1989;17:3335–3346. doi: 10.1093/nar/17.9.3335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Fujita T., Reis L., Watanabe N., Kimura Y., Taniguchi T., Vilcek J. Vol. 86. 1989. Induction of the transcription factor IRF-1 and interferon-β mRNAs by cytokines and activators of second messenger pathways; pp. 9936–9940. (Proc. Nad Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Fujita T., Kimura Y., Miyamoto M., Barsoumian E.L., Taniguchi T. Induction of endogenous IFN-α and IFN-β genes by a regulatory transcription factor, IRF-1. Nature. 1989;337:270–272. doi: 10.1038/337270a0. [DOI] [PubMed] [Google Scholar]
  86. Ghadge G.D., Swaminathan S., Katze M.G., Thimmapaya B. Vol. 88. 1991. Binding of the adenovirus VAI RNA to the interferon-induced 68-κDa protein kinase correlates with function; pp. 7140–7144. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Ghislain J., Sussman G., Goelz S., Ling L.E., Fish E. Configuration of the interferon-α/β receptor complex determines the context of the biological response. J. Biol. Chem. 1995;270:21785–21792. doi: 10.1074/jbc.270.37.21785. [DOI] [PubMed] [Google Scholar]
  88. Ghosh S.K., Kusari J., Bandyopadhyay S.K., Samanta H., Kumar R., Sen G.C. Cloning, sequencing and expression of two murine 2'-5'-oligoadenylate synthetases. J. Biol. Chem. 1991;266:15293–15299. [PubMed] [Google Scholar]
  89. Gillespie D., Carter W. Concerted evolution of human interferon a genes. J. Interferon Res. 1983;3:83–88. doi: 10.1089/jir.1983.3.83. [DOI] [PubMed] [Google Scholar]
  90. Ludwig H., Linkesch W., Chott A., Fritz E., Radaszkiewicz T.H. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet. 1989;i:634–637. doi: 10.1016/s0140-6736(89)92142-9. [DOI] [PubMed] [Google Scholar]
  91. Goeddel D.V., Yelverton E., Ullrich A. Human leukocyte interferon produced by E. coli is biologically active. Nature. 1980;287:411–416. doi: 10.1038/287411a0. [DOI] [PubMed] [Google Scholar]
  92. Goeddel D.V., Leung D.W., Dull T.J. The structure of eight distinct cloned human leukocyte cDNAs. Nature. 1981;290:20–26. doi: 10.1038/290020a0. [DOI] [PubMed] [Google Scholar]
  93. Goldstein D., Laszlo J. Interferon therapy in cancer: from imagination to interferon. Cancer Res. 1986;46:4315–4329. [PubMed] [Google Scholar]
  94. Goodbourn S., Maniatis T. Vol. 85. 1988. Overlapping positive and negative regulatory domains of the human p-interferon gene; pp. 1447–1451. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Goodbourn S., Burstein H., Maniatis T. The human β-interferon gene enhancer is under negative control. Cell. 1986;45:601–610. doi: 10.1016/0092-8674(86)90292-8. [DOI] [PubMed] [Google Scholar]
  96. Goodkin D.E. Interferon beta-lb. Lancet. 1994;344:1057–1060. doi: 10.1016/s0140-6736(94)91713-2. [DOI] [PubMed] [Google Scholar]
  97. Goren T., Fischer D.G., Rubinstein N. Human monocytes and lymphocytes produce different mixtures of α-interferon subtypes. J. Interferon Res. 1986;6:323–327. doi: 10.1089/jir.1986.6.323. [DOI] [PubMed] [Google Scholar]
  98. Gray P.W., Leung D.W., Pennica D. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature. 1982;295:503–508. doi: 10.1038/295503a0. [DOI] [PubMed] [Google Scholar]
  99. Greenway A.L., Overall M.L., Sattayasai N. Selective production of interferon-alpha subtypes by cultured peripheral blood mononuclear cells and lymphoblastoid cell lines. Immunology. 1992;75:182–188. [PMC free article] [PubMed] [Google Scholar]
  100. Gren E., Berzin V., Jansone I., Tsimanis A., Vishnevsky Y., Npsalons U. Novel human leukocyte interferon subtype and structural comparison of a interferon genes. J. Interferon Res. 1984;4:609–617. doi: 10.1089/jir.1984.4.609. [DOI] [PubMed] [Google Scholar]
  101. Gresser I. Role of interferon in resistance to viral infection in vivo. In: Vilcek J., De Maeyer E., editors. Interferon 2: Interferons and the Immune System. Elsevier; New York: 1984. pp. 221–247. [Google Scholar]
  102. Gresser I., Brouty-Boye D., Thomas M.-T., Macieira-Coelho A. Vol. 66. 1970. Interferon and cell division. I. Inhibition of the multiplication of mouse leukaemia L1210 cells in vitro by interferon preparations; pp. 1052–1058. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Gresser I., Maury C., Brouty-Boye D. Mechanism of antitumour effect of interferon in mice. Nature. 1972;239:167–168. doi: 10.1038/239167a0. [DOI] [PubMed] [Google Scholar]
  104. Gresser I., Belardelli F., Maury C., Maunoury M.T., Tovey M.G. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumours. J. Exp. Med. 1983;158:2095–2107. doi: 10.1084/jem.158.6.2095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Groopman J.E., Scadden D.T. Interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS) Ann. Intern. Med. 1989;10:335–337. doi: 10.7326/0003-4819-110-5-335. [DOI] [PubMed] [Google Scholar]
  106. Gross G., Mayr U., Bruns W., Grosveld F., Dahl H.H.M., Collins J. The structure of a thirty-six kilobase region of the human chromosome including the fibroblast interferon gene IFN-β. Nucleic Acids Res. 1981;9:2495–2507. doi: 10.1093/nar/9.11.2495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Grossberg S.E., Taylor J.L., Kushnaryov V.M. Interferon receptors and their role in interferon action. Experientia. 1989;45:508–513. doi: 10.1007/BF01990499. [DOI] [PubMed] [Google Scholar]
  108. Gupta S.L., Holmes S.L., Mehra L.L. Interferon action against reovirus: activation of interferon-induced protein kinase in mouse L929 cells upon reovirus infection. Virology. 1982;120:495–499. doi: 10.1016/0042-6822(82)90051-4. [DOI] [PubMed] [Google Scholar]
  109. Gupta S., Yan H., Wong L., Ralph S., Krolewski J., Schineller C. The SH2 domains of Stat 1 and Stat 2 mediate multiple interactions in the transduction of IFNα signals. EMBO J. 1996;15:1075–1084. [PMC free article] [PubMed] [Google Scholar]
  110. Gutch M.J., Reich N.C. Vol. 88. 1991. Regression of the interferon signal transduction pathway by the adenovirus E1A oncogene; pp. 7913–7917. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Gutterman J.U. Vol. 91. 1994. Cytokine therapeutics: lessons from interferon α; pp. 1198–1205. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Hannigan G.E., Lau A.S., Williams B.R. Differential human interferon alpha receptor expression on proliferating and non-proliferating cells. Eur. J. Biochem. 1986;157:187–193. doi: 10.1111/j.1432-1033.1986.tb09655.x. [DOI] [PubMed] [Google Scholar]
  113. Hansen T.R., Leaman D.W., Cross J.C., Mathialagan N., Bixby J.A., Roberts R.M. The genes for the trophoblast interferons and the related interferon all possess distinct 5'-promoter and 3'-flanking sequences. J. Biol. Chem. 1991;266:3060–3067. [PubMed] [Google Scholar]
  114. Harada H., Fujita T., Miyamoto M. Structurally similar, but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell. 1989;58:729–739. doi: 10.1016/0092-8674(89)90107-4. [DOI] [PubMed] [Google Scholar]
  115. Harada H., Willison K., Sakakibara J., Miyamoto M., Fujita T., Taniguchi T. Absence of type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) are developmentally regulated. Cell. 1990;63:303–312. doi: 10.1016/0092-8674(90)90163-9. [DOI] [PubMed] [Google Scholar]
  116. Harada H., Kitagawa M., Tanaka N. Anti-oncogenic and oncogenic potentials of interferon regulatory factors 1 and 2. Science. 1993;259:971–974. doi: 10.1126/science.8438157. [DOI] [PubMed] [Google Scholar]
  117. Hartshorn K.L., Neumeyer D., Vogt M.W., Schooley R.T., Hirsh M.S. Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro. AIDS Res. Human Retrovir. 1987;3:125–133. doi: 10.1089/aid.1987.3.125. [DOI] [PubMed] [Google Scholar]
  118. Hauptmann R., Swetly P. A novel class of human type I interferons. Nucleic Acids Res. 1985;13:4739–4749. doi: 10.1093/nar/13.13.4739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Havell E.A., Hayes T.G., Vilcek J. Synthesis of two distinct interferons by human fibroblasts. Virology. 1978;89:330–334. doi: 10.1016/0042-6822(78)90068-5. [DOI] [PubMed] [Google Scholar]
  120. Healy G.B., Gelber R.D., Trowbridge A.L., Grundfast K.M., Ruben R.J., Price K.N. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. N. Engl. J. Med. 1988;319:401–407. doi: 10.1056/NEJM198808183190704. [DOI] [PubMed] [Google Scholar]
  121. Henco K., Brosius J., Fujisawa A. Structural relationship of human interferon-α genes and pseudogenes. J. Mol. Biol. 1985;185:227–260. doi: 10.1016/0022-2836(85)90401-2. [DOI] [PubMed] [Google Scholar]
  122. Henry L., Sizun J., Turleau C., Boue J., Azoulay M., Junien C. The gene for human fibroblast interferon (IFB) maps to 9p21. Hum. Genet. 1984;68:67–70. doi: 10.1007/BF00293875. [DOI] [PubMed] [Google Scholar]
  123. Heron I., Hokland M., Berg K. Vol. 75. 1978. Enhanced expression of β2-microglobulin and HLA antigens on human lymphoid cells by interferon; pp. 6215–6219. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Hertzog P.J., Hwang S.Y., Holland K.A., Tymms M.J., Iannello R., Kola I. A gene on human chromosome 21 located in the region 21q22.2 to 21q22.3 encodes a factor necessary for signal transduction and antiviral response to type I int. J. Biol. Chem. 1994;269:14088–14093. [PubMed] [Google Scholar]
  125. Higashi Y., Sokawa Y., Watanabe Y. Structure and expression of a cloned cDNA for mouse interferon-β. J. Biol. Chem. 1983;258:9522–9529. [PubMed] [Google Scholar]
  126. Himmler A., Hauptmann R., Adolf G.R., Swetly P. Structure and expression in Escherichia coli of canine alpha-interferon genes. J. Interferon Res. 1987;7:173–183. doi: 10.1089/jir.1987.7.173. [DOI] [PubMed] [Google Scholar]
  127. Hiscott J., Cantell K., Weissmann C. Differential expression of human interferon genes. Nucleic Acids Res. 1984;12:3727–3746. doi: 10.1093/nar/12.9.3727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. iHiscott J., Alper D., Cohen L. Induction of human interferon gene expression is associated with a nuclear-factor that interacts with the NFϰB site of the human immunodeficiency virus enha. J. Virol. 1989;65:2557–2566. doi: 10.1128/jvi.63.6.2557-2566.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Hokland P., Berg K. Interferon enhances the antibody-dependent cellular cytotoxicity (ADCC) of human polymorphonuclear leukocytes. J. Immunol. 1981;127:1585–1588. [PubMed] [Google Scholar]
  130. Horisberger M., Di Marco S. Interferon-alpha hybrids. Pharmac. Ther. 1995;66:507–534. doi: 10.1016/0163-7258(95)00008-5. [DOI] [PubMed] [Google Scholar]
  131. Hoskins M. A protective action of neurotropic against viserotropic yellow fever virus in Macacus rhesus. Am. J. Trop. Med. Hyg. 1935;15:675–680. [Google Scholar]
  132. Hosoi K., Utsumi J., Kitagawa T., Shimizu H., Kobayashi S. Structural characterization of fibroblast human interferon-beta. J. Interferon Res. 1988;8:375–384. doi: 10.1089/jir.1988.8.375. [DOI] [PubMed] [Google Scholar]
  133. Houghton M., Jackson I.J., Porter A.G. The absence of introns within a human fibroblast interferon gene. Nucleic Acids Res. 1981;9:247–266. doi: 10.1093/nar/9.2.247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Hovanessian A.G. Interferon-induced and double-stranded RNA-activated enzymes: a specific protein kinase and 2',5'-oligoadenylate synthetases. J. Interferon Res. 1991;11:199–205. doi: 10.1089/jir.1991.11.199. [DOI] [PubMed] [Google Scholar]
  135. Hu R., Gan Y., Liu J., Miller D., Zoon K.C. Evidence for multiple binding sites for several components of human lymphoblastoid interferon-α. J. Biol. Chem. 1993;268:12591–12595. [PubMed] [Google Scholar]
  136. Hug H., Costas M., Staeheli P., Aebi M., Weissmann C. Organisation of the murine Mx gene and characterisation of its interferon-inducible promoter. Experientia. 1988;44:A23. doi: 10.1128/mcb.8.8.3065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. IFNB Multiple Sclerosis Study Group Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled. Neurology. 1993;43:655–661. doi: 10.1212/wnl.43.4.655. [DOI] [PubMed] [Google Scholar]
  138. Ihle J. Cytokine receptor signalling. Nature. 1995;377:591–594. doi: 10.1038/377591a0. [DOI] [PubMed] [Google Scholar]
  139. Ihle J. STATs: signal transducers and activators of transcription. Cell. 1996;84:331–334. doi: 10.1016/s0092-8674(00)81277-5. [DOI] [PubMed] [Google Scholar]
  140. Ihle J., Kerr I. JAKs and STATs in signaling by the cytokine receptor superfamily. Trends Genet. 1995;11:69–74. doi: 10.1016/s0168-9525(00)89000-9. [DOI] [PubMed] [Google Scholar]
  141. Isaacs A., Lindemann J. Vol. 147. 1957. Virus interference. I. The interferon; pp. 258–267. (Proc. Roy. Soc. B.). [Google Scholar]
  142. Jacobs L., O'Malley J., Freeman A., Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science. 1981;214:1026–1028. doi: 10.1126/science.6171035. [DOI] [PubMed] [Google Scholar]
  143. Jacobs L., Salazar A.M., Herndon R. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis: results of a multicenter, double-blind study. Arch. Neurol. 1987;44:589–595. doi: 10.1001/archneur.1987.00520180013008. [DOI] [PubMed] [Google Scholar]
  144. Jacobs L., Cookfair D., Rudick R. A phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis: current status. Ann. Neurol. 1993;34:310. [Google Scholar]
  145. James R.I., Menaya J., Hudson K. Role of protein kinase C in induction of gene expression and inhibition of cell proliferation by interferon α. Eur. J. Biochem. 1992;209:813–822. doi: 10.1111/j.1432-1033.1992.tb17352.x. [DOI] [PubMed] [Google Scholar]
  146. Johnson P.W.M., Selby P.J. The treatment of multiple myeloma—an important MRC trial. Br. J. Cancer. 1994;70:781–785. doi: 10.1038/bjc.1994.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Joshi A.R., Sarkar I.H., Gupta S.L. Interferon receptors. Crosslinking of human leukocyte alpha-2 to its receptor on human cells. J. Biol. Chem. 1982;257:13884–13887. [PubMed] [Google Scholar]
  148. Kalvakolanu D.V.R., Bandyopadhyay S.K., Harter M.L., Sen G.C. Vol. 88. 1991. Inhibition of interferon-inducible gene expression by adenovirus ElA proteins: block in transcriptional complex formation; pp. 7459–7463. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Keller A.D., Maniatis T. Identification and characterisation of a novel repressor of interferon-β expression. Genes Dev. 1991;5:868–879. doi: 10.1101/gad.5.5.868. [DOI] [PubMed] [Google Scholar]
  150. Kessler D.S., Levy D.E. Protein kinase activity required for an early step in interferon-α signalling. J. Biol. Chem. 1991;266:23471–23476. [PubMed] [Google Scholar]
  151. Kessler D.S., Levy D.E., Pine R., Darnell J.E.J. Vol. 85. 1988. Two interferon-induced nuclear factors bind a single promoter element in interferon-stimulated genes; pp. 8521–8525. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Knight E. Vol. 73. 1976. Interferon: purification and initial characterisation from diploid cells; pp. 520–523. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  153. Knight E.J., Hunkapillar M.W., Korant B.D., Hardy R.W.F., Hood L.E. Human fibroblast interferon: amino acid analysis and amino terminal amino acid sequence. Science. 1980;207:525–526. doi: 10.1126/science.7352259. [DOI] [PubMed] [Google Scholar]
  154. Korn A., Rose D., Fish E. Three-dimensional model of a human interferon alpha consensus sequence. J. Interferon Res. 1994;14:1–9. doi: 10.1089/jir.1994.14.1. [DOI] [PubMed] [Google Scholar]
  155. Koromilas A.E., Roy S., Barber G.N., Katze M.G., Sononberg N. Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science. 1992;257:1685–1687. doi: 10.1126/science.1382315. [DOI] [PubMed] [Google Scholar]
  156. Kumar R., Choubey D., Lengyel P., Sen G.C. Studies on the role of the 2'-5'-oligoadenylate synthetase-RNase L pathway in β-interferon-mediated inhibition of encephalomyocarditis virus replication. J. Virol. 1988;62:3175–3181. doi: 10.1128/jvi.62.9.3175-3181.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  157. Kumar R., Atlas F. Vol. 89. 1992. Interferon a induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: role in growth regulation; pp. 6599–6603. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Lane H.C., Davey V., Kovacs J.A. Interferon alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection: a randomized, placebo-controlled trial. Ann. Intern. Med. 1990;112:805–811. doi: 10.7326/0003-4819-112-11-805. [DOI] [PubMed] [Google Scholar]
  159. Langer J.A., Pestka S. Structure of interferons. Pharmac. Ther. 1985;27:371–401. doi: 10.1016/0163-7258(85)90076-2. [DOI] [PubMed] [Google Scholar]
  160. Langer J.A., Pestka S. Interferon receptors. Immunology Today. 1988;9:393–400. doi: 10.1016/0167-5699(88)91241-8. [DOI] [PubMed] [Google Scholar]
  161. Lawn R.M., Adelman J., Dull T.J., Gross M., Goeddel D., Ullrich A. DNA sequence of two closely linked human leukocyte interferon genes. Science. 1981;212:1159–1162. doi: 10.1126/science.6165082. [DOI] [PubMed] [Google Scholar]
  162. Lawn R.M., Gross M., Houck C.M., Franke A.E., Gray P.J., Goeddel D.V. Vol. 78. 1981. DNA sequence of a major human leukocyte interferon gene; pp. 5435–5439. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  163. Leblanc J.-F., Cohen L., Rodrigues M., Hiscott J. Synergism between distinct enhanson domains in viral induction of human beta interferon gene. Mol. Cell. Biol. 1990;10:3987–3993. doi: 10.1128/mcb.10.8.3987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Lee T.G., Tomita J., Hovanessian A.G., Katze M.G. Characterization and regulation of the 58,000-dalton cellular inhibition of the interferon-induced, dsRNA-activated protein kinase. J. Biol. Chem. 1992;267:14238–14243. [PubMed] [Google Scholar]
  165. Lenardo M.J., Fan C.-M., Maniatis T., Baltimore D. The involvement of NF-ϰB in p-interferon gene regulation reveals its role as a widely inducible mediator of signal transduction. Cell. 1989;57:287–294. doi: 10.1016/0092-8674(89)90966-5. [DOI] [PubMed] [Google Scholar]
  166. Lengyel P. Biochemistry of interferons and their actions. Annu. Rev. Biochem. 1982;51:251–282. doi: 10.1146/annurev.bi.51.070182.001343. [DOI] [PubMed] [Google Scholar]
  167. Lengyel P. Vol. 90. 1993. Tumor-suppressor genes: news about the interferon connection; pp. 5893–5895. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Levy W.P., Shively J., Rubinstein M., Del Valle U., Pestka S. Vol. 77. 1980. Amino-terminal amino acid sequence of human leukocyte interferon; pp. 5102–5104. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  169. iLevy W.P., Rubinstein M., Shively J. Vol. 78. 1981. Amino acid sequence of a human leukocyte interferon; pp. 6186–6190. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Lewin A.R., Reid L.E., McMahon M., Stark G.R., Kerr I.M. Molecular analysis of a human interferon-inducible gene family. Eur. J. Biochem. 1991;199:417–423. doi: 10.1111/j.1432-1033.1991.tb16139.x. [DOI] [PubMed] [Google Scholar]
  171. Loeb K.R., Haas A.L. The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J. Biol. Chem. 1992;267:7806–7813. [PubMed] [Google Scholar]
  172. Lutfalla G., Gardiner K., Proudhon D., Vielh E., Uze G. The structure of the human interferon α/β receptor gene. J. Biol. Chem. 1992;267:2802–2809. [PubMed] [Google Scholar]
  173. Lutfalla G., Holland S., Cinato E. Mutant U5A cells are complemented by an interferon-αβ receptor subunit generated by alternative processing of a new member of a cytokine receptor gene clu. EMBO J. 1995;14:5100–5108. doi: 10.1002/j.1460-2075.1995.tb00192.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  174. MacDonald N.J., Kuhl D., Maguire D. Different pathways mediate virus inducibility of the human IFN-αl and IFN-β genes. Cell. 1990;60:767–779. doi: 10.1016/0092-8674(90)90091-r. [DOI] [PubMed] [Google Scholar]
  175. Mandelli F., Awisati G., Amadori S. Maintenance treatment with recombinant interferon alpha 2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med. 1990;322:1430–1434. doi: 10.1056/NEJM199005173222005. [DOI] [PubMed] [Google Scholar]
  176. Mantei N., Weissmann C. Controlled transcription of a human α-interferon gene introduced into mouse L-cells. Nature. 1982;297:128–132. doi: 10.1038/297128a0. [DOI] [PubMed] [Google Scholar]
  177. Mantei N., Schwartzstein M., Streuli M., Panem S., Nagata S., Weissmann C. The nucleotide sequence of a cloned human leukocyte interferon cDNA. Gene. 1980;10:1–10. doi: 10.1016/0378-1119(80)90137-7. [DOI] [PubMed] [Google Scholar]
  178. Mark D.F., Lu S.D., Creasey A.A., Yamamoto R., Lin L.S. Vol. 81. 1981. Site-specific mutagenesis of the human fibroblast interferon gene; pp. 5662–5666. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. Mathews M.B., Shenk T. Adenovirus virus-associated RNA and translational control. J. Virol. 1991;65:5657–5662. doi: 10.1128/jvi.65.11.5657-5662.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  180. Matsuyama T., Kimura T., Kitagawa M. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell. 1993;75:83–97. [PubMed] [Google Scholar]
  181. Meager A., Graves H., Burke D.C., Swallow D.M. Involvement of a gene on chromosome 9 in interferon production. Nature. 1979;280:493–495. doi: 10.1038/280493a0. [DOI] [PubMed] [Google Scholar]
  182. Meager A., Graves H., Shuttleworth J., Zucker N. Interferon production: variation in yields from human cell lines. Infect. Immun. 1979;25:658–663. doi: 10.1128/iai.25.2.658-663.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  183. Meager A., Graves H., Walker J.R., Burke D.C., Swallow D.M., Westerveld A. Somatic cell genetics of human interferon production in human-rodent cell lines. J. Gen. Virol. 1979;45:309–321. doi: 10.1099/0022-1317-45-2-309. [DOI] [PubMed] [Google Scholar]
  184. Meager A., Shuttleworth J., Just M., Boseley P., Morser J. The effect of hypertonic salt on interferon and interferon mRNA synthesis in human MG63 cells. J. Gen. Virol. 1982;59:177–181. doi: 10.1099/0022-1317-59-1-177. [DOI] [PubMed] [Google Scholar]
  185. Melén K., Ronni T., Broni B., Krug R.M., von Bonsdorff C-H., Julkunen I. Interferon-induced Mx proteins form oligomers and contain a putative leucine zipper. J. Biol. Chem. 1992;267:25898–25992. [PubMed] [Google Scholar]
  186. Meraz M., White J., Sheehan K. Targeted disruption of the Stat 1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996;84:431–442. doi: 10.1016/s0092-8674(00)81288-x. [DOI] [PubMed] [Google Scholar]
  187. Meurs E.F., Galabru J., Barber G.N., Katze M.G., Hovanessian A.G. Vol. 90. 1993. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase; pp. 232–236. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  188. Mijata T., Hayashida H. Recent divergence from a common ancestor of human IFN-α genes. Nature. 1982;295:165–168. doi: 10.1038/295165a0. [DOI] [PubMed] [Google Scholar]
  189. Miyamoto N.G., Samuel C.E. Mechanism of interferon action. Interferon mediated inhibition of reovirus mRNA translation in the absence of detectable mRNA degradation but in the presence. Virology. 1980;107:461–475. doi: 10.1016/0042-6822(80)90313-x. [DOI] [PubMed] [Google Scholar]
  190. Miyamoto M., Fumita T., Kimura Y. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-β gene regulatory elements. Cell. 1988;54:903–913. doi: 10.1016/s0092-8674(88)91307-4. [DOI] [PubMed] [Google Scholar]
  191. Morehead H., Johnston P.D., Wetzel R. Roles of the 29-138 disulfide bond of subtype A of human a interferon in its antiviral activity and conformational stability. Biochemistry. 1984;23:2500–2507. doi: 10.1021/bi00306a028. [DOI] [PubMed] [Google Scholar]
  192. Müller M., Briscoe J., Laxton C. The protein tyrosine kinase JAK1 complements defects in the IFN-α/β and -γ signal transduction. Nature. 1993;366:129–135. doi: 10.1038/366129a0. [DOI] [PubMed] [Google Scholar]
  193. Müller U., Steinhoff U., Reis L. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264:1918–1924. doi: 10.1126/science.8009221. [DOI] [PubMed] [Google Scholar]
  194. Naf D., Hardin S.E., Weissmann C. Vol. 88. 1991. Multimerization of AAGTGA and GAAAGT generates sequences that mediate virus inducibility by mimicking an interferon promoter element; pp. 1369–1373. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  195. Nagata S., Mantei N., Weissmann C. The structure of one of the eight or more distinct chromosomal genes for human interferon-α. Nature. 1980;287:401–408. doi: 10.1038/287401a0. [DOI] [PubMed] [Google Scholar]
  196. Neighbor P.A., Bloom B.R. Vol. 76. 1979. Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis; pp. 476–480. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  197. Nevins J.R. Transcriptional activation by viral regulatory proteins. Trends Biochem. Sci. 1991;16:435–439. doi: 10.1016/0968-0004(91)90171-q. [DOI] [PubMed] [Google Scholar]
  198. Nourbakhsh M., Hoffmann K., Hauser H. Interferon-β promoters contain a DNA element that acts as a position-independent silencer on the NF-ϰB site. EMBO J. 1993;12:451–459. doi: 10.1002/j.1460-2075.1993.tb05677.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  199. Novick D., Cohen B., Rubinstein M. The human interferon α/β receptor: characterisation and molecular cloning. Cell. 1994;77:391–400. doi: 10.1016/0092-8674(94)90154-6. [DOI] [PubMed] [Google Scholar]
  200. Oberg K., Aim G., Magnusson A. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor. J. Natl Cancer Inst. 1989;81:531–535. doi: 10.1093/jnci/81.7.531. [DOI] [PubMed] [Google Scholar]
  201. Ohlsson M., Feder J., Cavalli-Sforza L.L., von Gabain A. Vol. 82. 1985. Close linkage of α and β interferons and infrequent duplication of p interferon in humans; pp. 4473–4476. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  202. Owerbach D., Rutter W.J., Shows T.B., Gray P., Goeddel D.V., Lawn R. Vol. 78. 1981. Leukocyte and fibroblast interferon genes are located on human chromosome 9; pp. 3123–3127. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  203. Paty D.W., Li D.K.B., UBC MS MRI Study Group and IFNB Multiple Sclerosis Study Group Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-contro. Neurology. 1993;43:662–667. doi: 10.1212/wnl.43.4.662. [DOI] [PubMed] [Google Scholar]
  204. Pestka S., Langer J.A., Zoon K.C., Samuel C.E. Interferons and their actions. Annu. Rev. Biochem. 1987;56:727–777. doi: 10.1146/annurev.bi.56.070187.003455. [DOI] [PubMed] [Google Scholar]
  205. Pfeffer L.M., Eisenkraft B.L., Reich N.C. Vol. 88. 1991. Transmembrane signalling by interferon a involves diacylglycerol production and activation of ε isoform of protein kinase C in Daudi cells; pp. 7988–7992. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  206. Phillips A.W., Finter N.B., Burman C.J., Ball G.D. Large scale production of human interferon from lymphoblastoid cells. Methods Enzymol. 1986;119:35–38. doi: 10.1016/0076-6879(86)19006-9. [DOI] [PubMed] [Google Scholar]
  207. Pine R., Levy D.E., Reich N., Darnell J.E.J. Purification and cloning of interferon-stimulated gene factor 2 (ISGF2): ISGF2 (IRF-1) can bind to the promoters of both beta interferon and interferon-stimul. Mol. Cell. Biol. 1990;10:2448–2457. doi: 10.1128/mcb.10.6.2448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  208. Platanias L.C., Uddin S., Colamonici O.R. Tyrosine phosphorylation of the α and β subunits of the α and β subunits of the type I interferon receptor. J. Biol. Chem. 1994;269:17761–17764. [PubMed] [Google Scholar]
  209. Porter A.C.G., Itzhaki J.E. Gene targeting in human somatic cells: complete inactivation of an interferon-inducible gene. Euro. J. Biochem. 1993;218:273–281. doi: 10.1111/j.1432-1033.1993.tb18375.x. [DOI] [PubMed] [Google Scholar]
  210. Rager-Zisman B., Bloom B.R. Interferons and natural killer cells. Br. Med. Bull. 1985;41:22–27. doi: 10.1093/oxfordjournals.bmb.a072018. [DOI] [PubMed] [Google Scholar]
  211. Ragg H., Weissmann C. Not more than 117 base pairs of 5'-flanking sequence are required for inducible expression of a human IFN-α gene. Nature. 1983;303:439–442. doi: 10.1038/303439a0. [DOI] [PubMed] [Google Scholar]
  212. Raziuddin A., Gupta S.L. Receptors for human interferon-alpha: two forms of interferon-receptor complexes identified by chemical cross-linking. In: Williams B.R.G., Silverman R.H., editors. The 2-5A System: Molecular and Clinical Aspects of the Interferon-Regulated Pathway. Alan Liss; Amsterdam: 1985. pp. 219–240. [PubMed] [Google Scholar]
  213. Raziuddin A., Sarkar F.H., Dutkowski R., Shulman L., Ruddle F.H., Gupta S.L. Vol. 81. 1984. Receptors for human a and β interferon but not for γ interferon are specified by human chromosome 21; pp. 5504–5508. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  214. Rehberg E., Kelder B., Hoal E.G., Pestka S. Specific molecular activities of recombinant and hybrid leukocyte interferons. J. Biol. Chem. 1982;257:11497–11502. [PubMed] [Google Scholar]
  215. Reich N.C., Pfeffer L.M. Vol. 87. 1990. Evidence for involvement of protein kinase C in the cellular response to interferon α; pp. 8761–8765. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  216. Reid L.E., Brasnett A.H., Gilbert C.S. Vol. 86. 1989. A single DNA response element can confer inducibility by both α- and γ-interferons; pp. 840–844. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  217. Reid T.R., Race E.R., Wolff B.H., Friedman R.M., Merigan T.C., Basham T.Y. Enhanced in vivo therapeutic response to interferon in mice with an in vitro interferon-resistant B-cell lymphoma. Cancer Res. 1989;49:4163–4169. [PubMed] [Google Scholar]
  218. Reis F.L., Ruffner H., Stark G., Aguet M., Weissmann C. Mice devoid of interferon regulatory factor (IRF-1) show normal expression of type I interferon genes. EMBO J. 1994;13:4798–4806. doi: 10.1002/j.1460-2075.1994.tb06805.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  219. Reis L.F. L., Harada H., Wolchok J.D., Taniguchi T., Vilcek J. Critical role of a common transcription factor, IRF-1, in the regulation of IFN-β and IFN-inducible genes. EMBO J. 1992;11:185–193. doi: 10.1002/j.1460-2075.1992.tb05041.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  220. Resnitzky D., Tiefenbrun N., Berissi H., Kimchi A. Vol. 89. 1992. Interferons and interleukin-6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells; pp. 402–406. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  221. Revel M., Chebath J. Interferon-activated genes. Trends Biochem. Sci. 1986;11:166–170. [Google Scholar]
  222. Revel M., Cohen B., Abramovich C., Novick D., Rubinstein M., Shulman L. Components of the human type I IFN receptor system. J. Interferon Res. 1991;11:561. supplement. [Google Scholar]
  223. Rhodes J., Ivanyi J., Cozens P. Antigen presentation by human monocytes: effects of modifying major histocompatibility complex class II antigen expression and interleukin 1 production by usi. Eur. J. Immunol. 1986;16:370–375. doi: 10.1002/eji.1830160410. [DOI] [PubMed] [Google Scholar]
  224. Rice A.P., Duncan R., Hershey J.W.B., Kerr I.M. Double-stranded RNA-dependent protein kinase and 2-5A system are both activated in interferon-treated, encephalomyocarditis virus-infected HeLa cells. J. Virol. 1985;54:894–898. doi: 10.1128/jvi.54.3.894-898.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  225. Rigby W.F.C., Ball E.D., Guyre P.M., Fanger M.W. The effect of recombinant-DNA-derived interferons on the growth of myeloid progenitor cells. Blood. 1985;65:858–861. [PubMed] [Google Scholar]
  226. Rinehart J., Malspeis L., Young D., Neidhart J. Phase I/II trial of human recombinant β-interferon serine in patients with renal cell carcinoma. Cancer Res. 1986;46:5364–5367. [PubMed] [Google Scholar]
  227. oberts R.M., Cross J.C., Leaman D.W. Interferons as hormones of pregnancy. Endocrine Rev. 1992;13:432–452. doi: 10.1210/edrv-13-3-432. [DOI] [PubMed] [Google Scholar]
  228. Roha tiner A.Z., Prior P., Burton A., Balkwill F., Lister T.A. Central nervous system toxicity of interferons. Prog. Exp. Tumor Res. 1985;29:197–202. doi: 10.1159/000411640. [DOI] [PubMed] [Google Scholar]
  229. Ronni T., Melén K., Malygin A., Julkunen I. Control of IFN-inducible MxA gene expression in human cells. J. Immunol. 1993;150:1715–1726. [PubMed] [Google Scholar]
  230. Rubin B.Y., Anderson S.L., Lunn R.M. Tumour necrosis factor and IFN induce a common set of proteins. J. Immunol. 1988;141:1180–1184. [PubMed] [Google Scholar]
  231. Rubinstein M., Orchansky P. The interferon receptors. CRC Crit. Rev. Biochem. 1986;21:249–270. doi: 10.3109/10409238609113613. [DOI] [PubMed] [Google Scholar]
  232. Rubinstein M., Rubinstein S., Familetti P.C. Human leukocyte interferon purified to homogeneity. Science. 1978;202:1289–1290. doi: 10.1126/science.725605. [DOI] [PubMed] [Google Scholar]
  233. Rubinstein M., Levy W.P., Moschera J.A. Human leukocyte interferon: isolation and characterisation of several molecular forms. Arch. Biochem. Biophys. 1981;210:307–318. doi: 10.1016/0003-9861(81)90194-6. [DOI] [PubMed] [Google Scholar]
  234. Ruffner H., Reis L.F., Naf D., Weissmann C. Vol. 90. 1993. Induction of type I interferon genes and interferon-inducible genes in embryonal stem cells devoid of interferon regulatory factor I; pp. 11503–11507. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  235. Ryals J., Dierks P., Ragg H., Weissmann C. A 46-nucleotide promoter segment from an IFN-α gene renders an unrelated promoter inducible by virus. Cell. 1985;41:497–507. doi: 10.1016/s0092-8674(85)80023-4. [DOI] [PubMed] [Google Scholar]
  236. Samuel C.E. Interferon induction of the antiviral state proteins induced by interferons and their possible roles in the antiviral mechanisms of action. In: Pfeffer L.M., editor. Interferon Actions. CRC Press; New York: 1987. pp. 110–130. [Google Scholar]
  237. Saven A., Piro L.D. Treatment of hairy cell leukaemia. Blood. 1992;79:1111–1120. [PubMed] [Google Scholar]
  238. Schindler C., Shuai K., Prezioso V.R., Darnell J.E.J. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science. 1992;257:809–813. doi: 10.1126/science.1496401. [DOI] [PubMed] [Google Scholar]
  239. Schlesinger R.W. Interference between animal viruses. In: Barnet F.M., Stanley W.M., editors. vol. III. Academic Press; Boca Raton, FL.: 1959. pp. 157–194. (The Viruses). [Google Scholar]
  240. Schneider A., Papendick U., Gissmann L., De Villiers E.M. Interferon treatment of human genital papilloma virus infection: importance of viral type. Int. J. Cancer. 1987;40:610–614. doi: 10.1002/ijc.2910400506. [DOI] [PubMed] [Google Scholar]
  241. Schwemmle M., Staeheli P. The interferon-induced 67-kDa guanylate-binding protein (hGBPl) is a GTPase that converts GTP to GMP. J. Biol. Chem. 1994;269:11299–11305. [PubMed] [Google Scholar]
  242. Scott G.M., Philpotts R.J., Wallace J., Gauci C.L., Greiner J., Tyrell D.A.J. Prevention of rhinovirus colds by human interferon alpha-2 from E. colt. Lancet. 1982;ii:186–188. doi: 10.1016/s0140-6736(82)91031-5. [DOI] [PubMed] [Google Scholar]
  243. Sekar V., Atmar V.J., Joshi A.R., Krim M., Kuehn G. Inhibition of ornithine decarboxylase in human fibroblast cells by type I and type II interferons. Biochem. Biophys. Res. Commun. 1983;114:950–954. doi: 10.1016/0006-291x(83)90652-6. [DOI] [PubMed] [Google Scholar]
  244. Sen G.C., Lengyel P. The interferon system: a bird's eye view of the biochemistry. J. Biol. Chem. 1992;267:5017–5020. [PubMed] [Google Scholar]
  245. Senda T., Shimazu T., Matsuda S. Three-dimensional crystal structure of recombinant murine interferon-β. EMBO J. 1992;11:3193–3201. doi: 10.1002/j.1460-2075.1992.tb05396.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  246. Shafferman A., Velan B., Cohen S., Leitner M., Grosfeld H. Specific residues within an amino-terminal domain of 35 residues of interferon-α are responsible for recognition of the human interferon-α cell receptor a. J. Biol. Chem. 1987;262:6227–6237. [PubMed] [Google Scholar]
  247. Shaw G., Bol l W., Taira H., Mantei N., Lengyel P., Weissmann C. Structure and expression of cloned murine IFN-α genes. Nucleic Acids Res. 1983;11:555–573. doi: 10.1093/nar/11.3.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  248. Shaw G.D., Kamen R. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediators selective mRNA-degradation. Cell. 1986;46:659–667. doi: 10.1016/0092-8674(86)90341-7. [DOI] [PubMed] [Google Scholar]
  249. Shepard H.M., Leung D., Stebbing N., Goeddel D.V. A single amino acid change in IFN-βi abolishes its antiviral activity. Nature. 1981;294:563–565. doi: 10.1038/294563a0. [DOI] [PubMed] [Google Scholar]
  250. Shirono H., Kono K., Koga J., Hayashi S., Matsuo A., Hiratani H. Existence and unique N-terminal sequence of alpha II (omega) interferon in natural leukocyte interferon preparation. Biochem. Biophys. Res. Commun. 1990;168:16–21. doi: 10.1016/0006-291x(90)91668-i. [DOI] [PubMed] [Google Scholar]
  251. Shows T.B., Sakaguchi A.Y., Naylor S.L., Goeddel D.V., Lawn R.M. Clustering of leukocyte and fibroblast genes on human chromosome 9. Science. 1982;218:373–374. doi: 10.1126/science.6181564. [DOI] [PubMed] [Google Scholar]
  252. Shuai K., Horvath C.M., Tsai Huang L.H., Qureshi S.A., Cowburn D., Darnell J.E.J. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell. 1994;76:821–828. doi: 10.1016/0092-8674(94)90357-3. [DOI] [PubMed] [Google Scholar]
  253. Shulman L.M., Kamarck M.E., Slate D.L. Antibodies to chromosome 21 coded cell surface components block binding of human a interferon but not γ interferon to human cells. Virology. 1984;137:422–427. doi: 10.1016/0042-6822(84)90235-6. [DOI] [PubMed] [Google Scholar]
  254. Shuttleworth J., Morser J., Burke D.C. Expression of interferon-α and interferon-β genes in human lymphoblastoid (Namalwa) cells. Eur. J. Biochem. 1983;133:399–404. doi: 10.1111/j.1432-1033.1983.tb07476.x. [DOI] [PubMed] [Google Scholar]
  255. Sidky Y.A., Borden E.C. Inhibition of angiogenesis by interferons: effects on tumour- and lymphocyte-induced vascular responses. Cancer Res. 1987;47:5155–5161. [PubMed] [Google Scholar]
  256. Slate D.L., Shulman L., Lawrence J.B., Revel M., Ruddle F.H. Presence of human chromosome 21 alone is sufficient for hybrid cell sensitivity to human interferon. J. Virol. 1978;25:319–325. doi: 10.1128/jvi.25.1.319-325.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  257. Slate D.L., D'Eustachio P., Pravtcheva D. Chromosomal location of a human α interferon gene family. J. Exp. Med. 1982;155:1019–1024. doi: 10.1084/jem.155.4.1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  258. Soh J., Mariano T.M., Lim J.-Y. Expression of a functional human type I interferon receptor in hamster cells: application of functional yeast artificial chromosome (YAC) screening. J. Biol. Chem. 1994;269:18102–18110. [PubMed] [Google Scholar]
  259. Staeheli P. Interferon-induced proteins and the antiviral state. Adv. Virus Res. 1990;38:147–200. doi: 10.1016/s0065-3527(08)60862-3. [DOI] [PubMed] [Google Scholar]
  260. Steis R.G., Smith J.W., Urba W.J. Resistance to recombinant interferon alfa-2a in hairy-cell leukaemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med. 1988;318:1409–1413. doi: 10.1056/NEJM198806023182201. [DOI] [PubMed] [Google Scholar]
  261. Stewart W.E., II . Springer-Verlag; New York: 1979. The Interferon System; pp. 134–183. [Google Scholar]
  262. Stewart W.E.I., II, Blalock J.E., Burke D.C. Interferon nomenclature. Nature. 1980;286:110. doi: 10.1038/286110a0. [DOI] [PubMed] [Google Scholar]
  263. Stolfi R.L., Martin D.S., Sawyer R.C., Spiegelman S. Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid. Cancer Res. 1983;43:561–566. [PubMed] [Google Scholar]
  264. Streuli M., Nagata S., Weissmann C. At least three human type a interferons: structure of a2. Science. 1980;209:1343–1347. doi: 10.1126/science.6158094. [DOI] [PubMed] [Google Scholar]
  265. Streuli M., Hall A., Boll W., Stewart W.E., II, Nagata S., Weissmann C. Vol. 78. 1981. Target specificity of two species of human interferon-α produced in Escherichia coli and of hybrid molecules derived from them; pp. 2848–2852. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  266. Symons J., Alcami A., Smith G. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell. 1995;81:551–560. doi: 10.1016/0092-8674(95)90076-4. [DOI] [PubMed] [Google Scholar]
  267. Tan Y.H., Tischfield J., Ruddle F.H. The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21. J. Exp. Med. 1973;137:317–330. doi: 10.1084/jem.137.2.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  268. Taniguchi T., Mantei N., Schwarzstein M., Nagata S., Muramatsu M., Weissmann C. Human leukocyte and fibroblast interferons are structurally related. Nature. 1980;285:547–549. doi: 10.1038/285547a0. [DOI] [PubMed] [Google Scholar]
  269. Taylor J.L., Grossberg S.E. Recent progress in interferon research: molecular mechanisms of regulation, action, and virus circumvention. Virus Res. 1990;15:1026. doi: 10.1016/0168-1702(90)90010-9. [DOI] [PubMed] [Google Scholar]
  270. Thanos D., Maniatis T. The high mobility group protein HMGI (Y) is required for NF-ϰB-dependent virus induction of the human IFN-β gene. Cell. 1992;71:777–789. doi: 10.1016/0092-8674(92)90554-p. [DOI] [PubMed] [Google Scholar]
  271. Thomas N.S.B., Linch D.C. An intracellular 50kDa Feγ-binding protein is induced in human cells by α-IFN. J. Immunol. 1991;146:1649–1654. [PubMed] [Google Scholar]
  272. Thompson M.R., Zhang Z., Fournier A., Tan Y.H. Characterization of human beta-interferon-binding sites on human cells. J. Biol. Chem. 1985;360:563–567. [PubMed] [Google Scholar]
  273. Todokoro K., Kioussis D., Weissmann C. Two non-allelic human interferon a genes with identical coding regions. EMBO J. 1984;3:1809–1812. doi: 10.1002/j.1460-2075.1984.tb02050.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  274. Treanor J.J., Betts R.F., Erb S.M., Roth F.K., Dolin R. Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans. J. Infect. Dis. 1987;156:379–383. doi: 10.1093/infdis/156.2.379. [DOI] [PubMed] [Google Scholar]
  275. Trinchieri G., Perussia B. Human natural killer cells: biologic and pathologic aspects. Lab. Invest. 1984;50:489–503. [PubMed] [Google Scholar]
  276. Turner R.B., Fetton A., Kosak K., Kelsey D.K., Meschievitz C.K. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. J. Infect. Dis. 1986;154:443–447. doi: 10.1093/infdis/154.3.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  277. Ullrich A., Gray A., Goeddel D.V., Dull T.J. Nucleotide sequence of a portion of human chromosome 9 containing a leukocyte interferon gene cluster. J. Mol. Biol. 1982;156:467–486. doi: 10.1016/0022-2836(82)90261-3. [DOI] [PubMed] [Google Scholar]
  278. Utsumi J., Mizuno Y., Hosoi K. Characterization of four different mammalian-cell-derived recombinant human interferon-β1s. Eur. J. Biochem. 1989;181:545–553. doi: 10.1111/j.1432-1033.1989.tb14758.x. [DOI] [PubMed] [Google Scholar]
  279. Uze G., Mogensen K.E., Aguet M. Receptor dynamics of closely related ligands: “fast” and “slow” interferons. EMBO J. 1985;4:65–70. doi: 10.1002/j.1460-2075.1985.tb02318.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  280. Uze G., Bandu M.-T., Eid P., Grütter M., Mogensen K.E. Electrostatic interactions in the cellular dynamics of the interferon-receptor complex. Eur. J. Biochem. 1988;171:683–691. doi: 10.1111/j.1432-1033.1988.tb13840.x. [DOI] [PubMed] [Google Scholar]
  281. Uze G., Lutfalla G., Gresser I. Genetic transfer of a functional human interferon a receptor into mouse cells: cloning and expression of its cDNA. Cell. 1990;60:225–234. doi: 10.1016/0092-8674(90)90738-z. [DOI] [PubMed] [Google Scholar]
  282. Uze G., Lutfalla G., Eid P. Murine tumor cells expressing the gene for the human interferon αβ receptor elicit antibodies in syngeneic mice to the active form of the receptor. Eur. J. Immunol. 1991;21:447–451. doi: 10.1002/eji.1830210229. [DOI] [PubMed] [Google Scholar]
  283. Uze G., Lutfalla G., Bandu M.-T., Proudhon D., Mogensen K. Vol. 889. 1992. Behaviour of a cloned murine interferon alpha beta receptor expressed in homospecific or heterospecific background; pp. 4774–4778. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  284. Uze G., Lutfalla G., Mogensen K.E. α and β interferons and their receptor and their friends and relations. J. Interferon Cytokine Res. 1995;15:3–26. doi: 10.1089/jir.1995.15.3. [DOI] [PubMed] [Google Scholar]
  285. Vanden Broecke C., Pfeffer L.M. Characterization of interferon-alpha binding sites on human cell lines. J. Interferon Res. 1988;8:803–811. doi: 10.1089/jir.1988.8.803. [DOI] [PubMed] [Google Scholar]
  286. Vedantham S., Gamliel H., Golomb H.M. Mechanism of interferon action in hairy cell leukaemia: a model of effective cancer biotherapy. Cancer Res. 1992;52:1056–1066. [PubMed] [Google Scholar]
  287. Velasquez L., Fellous M., Stark G.R., Pellegrini S. A protein tyrosine kinase in the interferon α/β signalling pathway. Cell. 1992;70:313–322. doi: 10.1016/0092-8674(92)90105-l. [DOI] [PubMed] [Google Scholar]
  288. Velasquez L., Mogensen K., Barbieri G., Fellous M., Uze G., Pellegrini S. Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-α/β and for signal transduction. J. Biol. Chem. 1995;270:3327–3334. doi: 10.1074/jbc.270.7.3327. [DOI] [PubMed] [Google Scholar]
  289. Virelizier J.L., Gresser I. Role of interferon in the pathogenesis of viral diseases of mice as demonstrated by the use of anti-interferon serum. V. Protective role in mouse hepatitis vi. J. Immunol. 1978;120:1616–1619. [PubMed] [Google Scholar]
  290. Visvanathan K.V., Goodbourn S. Double-stranded RNA activates binding of NF-ϰB to an inducible element in human β-interferon promoter. EMBO J. 1989;8:1129–1138. doi: 10.1002/j.1460-2075.1989.tb03483.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  291. Vogel S.N., Finbloom D.S., English K.E., Rosenstreich D.L., Langreth S.G. Interferon-induced enhancement of macrophage Fc receptor expression: P-interferon treatment of C3H/HeJ macrophages results in increased numbers and density of. J. Immunol. 1983;130:1210–1214. [PubMed] [Google Scholar]
  292. von Wussow P., Pralle H., Hochkcppel H.-K. Effective natural interferon-α therapy in recombinant interferon-α-resistant patients with hairy cell leukaemia. Blood. 1991;78:38–43. [PubMed] [Google Scholar]
  293. Wadler S., Schwartz E.L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 1990;50:3473–3486. [PubMed] [Google Scholar]
  294. Wang C., Constantinescu S.N., MacEwan D.J. Vol. 90. 1993. Interferon a induces a protein kinase C-ε (PKC-ε) gene expression and a 4.7kb PKC-ε related transcript; pp. 6944–6948. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  295. Wang E., Pfeffer L.M., Tamm I. Vol. 78. 1981. Interferon increases the abundance of submembranous microfilaments in HeLa-S3 cells in suspension culture; pp. 6281–6285. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  296. Watanabe N., Sakakibara J., Hovanessian A.G., Taniguchi T., Fujita T. Activation of IFN-β element by IRF-1 requires a translational event in addition to IRF-1 synthesis. Nucleic Acids Res. 1991;19:4421–4428. doi: 10.1093/nar/19.16.4421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  297. Wathelet M.G., Clauss I.M., Content J., Huez G.A. Regulation of two interferon-inducible human genes by interferon, poly(rI):poly(rC) and viruses. Eur. J. Biochem. 1988;174:323–329. doi: 10.1111/j.1432-1033.1988.tb14101.x. [DOI] [PubMed] [Google Scholar]
  298. Wathelet M.G., Berr P.M., Huez G.A. Regulation of gene expression by cytokines and virus in human cells lacking the type-I interferon locus. Eur. J. Biochem. 1992;206:901–910. doi: 10.1111/j.1432-1033.1992.tb16999.x. [DOI] [PubMed] [Google Scholar]
  299. Week P.K., Apperson S., Stebbing N. Antiviral activities of hybrids of two major human leukocyte interferons. Nucleic Acids Res. 1981;9:6153–6166. doi: 10.1093/nar/9.22.6153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  300. Weidle U., Weissmann C. The 5'-flanking region of a human IFN-α gene mediates viral induction of transcription. Nature. 1983;303:442–446. doi: 10.1038/303442a0. [DOI] [PubMed] [Google Scholar]
  301. Weisz A., Marx P., Sharf R. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J. Biol. Chem. 1992;267:25589–25596. [PubMed] [Google Scholar]
  302. Whitaker-Dowling P., Youngner J.S. Vaccinia rescue of VSV from interferon-induced resistance: reversal of translation block and inhibition of protein kinase activity. Virology. 1983;131:128–136. doi: 10.1016/0042-6822(83)90539-1. [DOI] [PubMed] [Google Scholar]
  303. Whiteside S.T., Visvanathan K.V., Goodbourn S. Identification of novel factors that bind to the PRD1 region of the human β-interferon promoter. Nucleic Acids Res. 1992;20:1531–1538. doi: 10.1093/nar/20.7.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  304. Whittemore L.-A., Maniatis T. Vol. 87. 1990. Postinduction repression of the β-interferon gene is mediated through two positive regulatory domains; pp. 7799–7803. (Proc. Natl Acad. Sci. USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  305. Wide L., Wilander E. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumour. J. Natl Cancer Inst. 1989;81:531–535. doi: 10.1093/jnci/81.7.531. [DOI] [PubMed] [Google Scholar]
  306. Williams B.R.G. Transcriptional regulation of interferon-stimulated genes. Eur. J. Biochem. 1991;200:1–11. doi: 10.1111/j.1432-1033.1991.tb21041.x. [DOI] [PubMed] [Google Scholar]
  307. Williams B.R.G., Kerr I.M. Inhibition of protein synthesis by 2'-5' linked adenine oligonucleotides in intact cells. Nature. 1978;276:88–89. doi: 10.1038/276088a0. [DOI] [PubMed] [Google Scholar]
  308. Wilson V., Jeffreys A.J., Barrie P.A. A comparison of vertebrate interferon gene families detected by hybridisation with human interferon DNA. J. Mol. Biol. 1983;166:457–475. doi: 10.1016/s0022-2836(83)80281-2. [DOI] [PubMed] [Google Scholar]
  309. Wreschner D.H., James T.C., Silverman R.H., Kerr I.M. Ribosomal RNA cleavage, nuclease activation and 2-5A (ppp(A2'p)nA) in interferon treated cells. Nucleic Acids Res. 1981;9:1571–1581. doi: 10.1093/nar/9.7.1571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  310. Xanthoudakis S., Cohen L., Hiscott J. Multiple protein-DNA interactions with the human interferon-β regulatory element. J. Biol. Chem. 1989;264:1139–1145. [PubMed] [Google Scholar]
  311. Yan H., Krishnan K., Greenlund A. Phosphorylated interferon-α receptor 1 subunit (IFNaRl) acts as a docking site for the latent form of the 113 kDa STAT 2 protein. EMBO J. 1996;15:1064–1074. [PMC free article] [PubMed] [Google Scholar]
  312. Yonehara S., Yonehara-Takahashi M., Ishii A., Nagata S. Different binding of human interferon-αl and -α2 to common receptors on human and bovine cells. Studies with recombinant interferon produced in Escheri. J. Biol. Chem. 1983;258:9046–9049. [PubMed] [Google Scholar]
  313. Zhang K., Kumar R. Interferon-α inhibits cyclin E- and cyclin Dl-dependent CDK-2 kinase activity associated with RB protein and E2F in Daudi cells. Biochem. Biophys. Res. Commun. 1994;200:522–528. doi: 10.1006/bbrc.1994.1479. [DOI] [PubMed] [Google Scholar]
  314. Zhou A., Hassel B.A., Silverman R.H. Expressing cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell. 1993;72:753–765. doi: 10.1016/0092-8674(93)90403-d. [DOI] [PubMed] [Google Scholar]
  315. Zoon K.C., Wetzel R. Comparative structures of mammalian interferons. In: Crane P.E., Carter W.A., editors. Handbook of Experimental Pharmacology. Springer-Verlag; New York: 1984. pp. 79–100. [Google Scholar]
  316. Zoon K.C., Smith M.E., Bridgen P.J., Anfinsen C.B., Hunkapillar M.W, Hood L.E. Amino-terminal sequence of the major component of human lymphoblastoid interferon. Science. 1980;207:527–528. doi: 10.1126/science.7352260. [DOI] [PubMed] [Google Scholar]
  317. Zoon K.C., Miller D., Bekisz J. Purification and characterization of multiple components of human lymphoblastoid interferon-α. J. Biol. Chem. 1992;267:15210–15216. [PubMed] [Google Scholar]
  318. Zwarthoff E., Mooren A., Trapman J. Organization, structure and expression of murine interferon α genes. Nucleic Acids Res. 1985;13:791–804. doi: 10.1093/nar/13.3.791. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cytokines are provided here courtesy of Elsevier

RESOURCES